PharmNovo appoints Alexander Dahlquist as new CFO
The Swedish pharmaceutical company PharmNovo, currently at the clinical stage of pioneering a novel solution for neuropathic pain treatment, is pleased to announce the appointment of Alexander Dahlquist as the new CFO. Alexander Dahlquist will play a significant role in supporting the company's journey ahead.
Alexander Dahlquist succeeds Tommy Nilsson, who resigned this summer. "We extend our heartfelt gratitude to Tommy Nilsson for his dedicated service and valuable contributions," says Per von Mentzer, CEO of PharmNovo.
Alexander Dahlquist assumed the role of CFO in August and will leverage his extensive cross-industry experience to lead the company's financial functions. With a comprehensive background as a CFO, including his previous role at Coegin Pharma, and recent consultancy for small to medium-sized businesses, his insights will be integral in supporting PharmNovo’s mission to develop safe and effective treatments for neuropathic pain.
"We are thrilled to welcome Alexander Dahlquist to the PharmNovo team. His extensive experience in international finance and business management, along with his expertise in business control and process development, will play an important role in realising our vision to enhance the quality of life for people suffering from neuropathic pain," says Per von Mentzer, CEO of PharmNovo.
For more information, please contact:
Per von Mentzer, CEO
Phone +46 705 44 32 50
Email: per.von.mentzer@pharmnovo.com
About PharmNovo
PharmNovo AB is a clinical-stage pharmaceutical company focused on developing safe and effective drugs for neuropathic pain. In this area, there is currently a lack of sufficient treatments. The company's drug candidate, PN6047, effectively reduces nerve pain in animal models. The company also sees clinical potential in other areas, such as migraine, anxiety/depression, and chronic cough. PharmNovo, headquartered in Medicon Village in Lund, Sweden, was founded in 2008 by Dr Bengt von Mentzer, who has more than 30 years of experience in drug development and pain research at AstraZeneca. The team comprises prominent researchers in academia and industry, and the company has an extensive international network of leading expert advisors. To learn more, visit pharmnovo.com and follow PharmNovo at LinkedIn.
Tags:
